GRAL · GRAIL, Inc.
$67.87
-0.37 (-0.54%)
At close · Aug 14
Market Cap
$3.03B
Shares
44.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$67.87
Open$67.98
Day$66.35–68.71
52W close$31.42–116.06
Avg vol 30d620K
Short int7.5M · 16.8% float · 15.3d
Short vol79%
Last earningsAug 5, 2026
DataJun 2024–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
+1%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+58%
trailing
YTD return
−21%
this year
Relative strength
+44%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $67 › 200d $74 — 200d above 50d
Institutional flow
Accumulating
+0% holders QoQ · +64 funds added
Insider flow
Distributing
Net -$91.1K over 90 days · 100% sells
Short interest
Falling
16.77% of float · ▼ -3.1% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
372 holders — mid 2-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
EPS growth
+83%
Y/Y
Free cash flow
$-299.9M
Balance sheet
$249.7M
net cash
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jan 12, 2026
Cash burn
· 2026
up to $300M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Cash burn
· full year 2025
up to $290M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $67 › 200d $74 — 200d above 50d
Institutional flow
Accumulating
+0% holders QoQ · +64 funds added
Insider flow
Distributing
Net -$91.1K over 90 days · 100% sells
Short interest
Falling
16.77% of float · ▼ -3.1% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
372 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $31
Now $68 · 43%
Range high $116
vs 200-day avg -8%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$90.3M | Q2 2026 | — |
|
|
|||
| Adjusted gross profit non-GAAP | $21.6M | Q2 2026 | — |
|
|
|||
| Cash, cash equivalents, and short-term marketable securities | $861.6M | As of June 30, 2026 | — |
| Galleri test volume | 117,000 | First half of 2026 | — |
| Cash position | $823.1M | Q1 2026 | — |
| Galleri Tests Sold | 185,000 | full year 2025 | — |
| >800k In market with Galleri MCED test | 800K | as of January 12, 2026 | — |
| Cash burn | $274M | FY2025 | — |
| Commercial Galleri® tests sold to-date | 475K | as of January 12, 2026 | — |
| Prescriber growth over 2024 | 30% | as of December 31, 2025 | — |
| Test capacity at RTP site | 1M | as of January 12, 2026 | — |
| Total Galleri volume | 185K | FY2025 | — |
| Total Galleri volume growth over 2024 | 35% | FY2025 | — |
| Unique prescribers since launch | 17K | as of December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRAL
this stock
GRAIL, Inc.
|
$3.03B | -20.7% | +17.2% | — | 16.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRAL | -2.3% | -6.5% | +57.7% | -1.0% | -20.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.7% | -11.0% | +44.0% | -4.9% | -34.6% |
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
357 filings
345 filers
Visit website
Investor relations